Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial
Status: Recruiting
Sponsor: Australia Shineway Technology Pty Ltd
Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial
Status: Recruiting
Sponsor: Australia Shineway Technology Pty Ltd
Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO).
Status: Active
Sponsor: Biogen
A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer’s
Status: Recruiting
Sponsor: ImmuneBio
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer’s Disease.
Status: Recruiting
Sponsor: Cognition Therapeutics
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s disease (AD)
Status: Recruiting
Sponsor: ANAVEX Australia Pty Limited
AWARE: A Phase 2 Multiple Dose, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease.
Status: Active
Sponsor: AbbVie
DEFERIPRONE To Delay Dementia (The 3D Study): A Clinical Proof Of Concept Study.
Status: Recruiting
Sponsor: Neuroscience Trials Australia
GRADUATE: A Phase III Multicentre Randomised Double-blinded Placebo Controlled Parallel Group Efficacy and Safety Study of Gantanrumab in Patients with Prodromal to Mild AD.
Status: Recruiting
Sponsor: Roche